Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/02/2022* -- Results Q3 2022 -- 0.26 --
11/02/2022* 17:00 EST Earnings Call Q3 2022 -- -- --
08/09/2022 -- Results Q2 2022 0.28 0.24 14.55%
08/09/2022 17:00 EST Earnings Call Q2 2022 -- -- --
05/10/2022 -- Results Q1 2022 0.26 0.23 15.56%
05/10/2022 17:00 EST Earnings Call Q1 2022 -- -- --
02/17/2022 -- Results Q4 2021 0.35 0.16 125.0%
02/17/2022 17:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/02/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/09/2022
Beat/Miss Upgrade
Return Since -25.93%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
URL https://www.exelixis.com
Investor Relations URL https://ir.exelixis.com
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Nov. 02, 2022 (est.)
Last Earnings Release Aug. 09, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
291.7%
164.4%
103.9%
-35.30%
-10.42%
13.90%
-8.92%
-14.66%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-20.46%
--
-27.18%
-17.04%
-49.64%
3.57K%
-21.18%
-53.63%
28.37%
5.92%
-41.45%
103.4%
10.58%
32.13%
7.94%
-7.08%
35.99%
--
--
--
--
--
113.0%
56.35%
-49.03%
7.30%
4.68%
16.13%
25.06%
-6.73%
3.51%
66.74%
-25.31%
As of October 06, 2022.

Profile

Edit
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
URL https://www.exelixis.com
Investor Relations URL https://ir.exelixis.com
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Nov. 02, 2022 (est.)
Last Earnings Release Aug. 09, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
IDNA 6.263M USD 3.64%
VLLIX 8.120M USD 3.57%
VLIIX 11.03M USD 2.48%
PBE 5.630M USD 2.35%
FXH 23.51M USD 1.62%
FIJYX 28.17M USD 1.60%
JSMD 2.525M USD 1.52%
SMFCX 7.750M USD 1.41%
GSMQX 24.97M USD 1.26%
FBIOX 60.52M USD 1.20%
SMMV 7.156M USD 0.98%
XT 19.57M USD 0.72%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter EXEL Tweets